Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
复制标题
DOI：
10.1016/j.coph.2005.04.007
复制
发表时间：
2005-08-01
影响因子：
4
通讯作者：
Lyons, J
中科院分区：
文献类型：
--
作者：
Thompson, N;Lyons, J
自从发现Ras GTPase的激活突变与30%或更多的人类癌症相关以来，RAF/MEK/ERK途径一直是激烈的药物发现工作的焦点。在进入临床开发后期的新型分子靶向抗癌药物中，BAY 43-9006和PD0325901显示出相当大的前景。
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise,